Table 2.

Clinical studies of virus-specific T cells in solid organ transplantation

Cell Therapy	Indication	N	Date Study	Solid organ transplant	Virus-Specific T Cell Donor	Activation	Dose	Graft Versus Host Disease	Acute Rejection	Adverse Events	Disease-related Outcome
Autologous polyclonal EBV-specific Cytotoxic T cells	EBV+ PTLD	1	1999	Lung	Autologous	EBV infected lymphoblastoid cell lines	35 × 106 T cells×2 + 60×106 T cells×2	0	0	Death (pulmonary vein invasion with necrosis and hemorrhage)	PTLD near resolution
Allogeneic polyclonal EBV- specific cytotoxic T cells	EBV+ PTLD	5	2002	Liver (4), kidney (1) small bowel (3)	Frozen bank of CTLs derived from healthy blood donors	EBV infected lymphoblastoid cell lines	106/kg x one to six times	0	0	0	3/5 complete remission 2/5 no response
Autologous CMV-specific CD4+ and CD8+ cells	CMV	1	2009	Lung	Autologous	Overlapping IE‐1/pp65 peptide pools	107 T cells/m2 x 2	0	1	Death (rejection)	CMV resolution
Autologous CMV-specific CD4+ and CD8+ cells	CMV	1	2015	Lung	Autologous	Autologous PBMC coated with HLA class I restricted CMV peptide epitopes	Four infusions (total of 12 × 107 cells)	0	0	0	Persistent negative CMV PCR
Allogeneic Polyclonal CMV- specific CD4+ and CD8+ cells	CMV	1	2015	Kidney	3/6 HLA matched third-party donor	Overlapping peptides covering pp65	1.6 × 107 T cells/m2	0	0	Mild fever post VST infusion	At 1 yr CMV viral load declined from 5.5 M to 73 copies/ml
Allogenic BK- specific VST	BKV	3	2017	Kidney (1) kidney + heart (1) heart (1)	Adult volunteers	IFN-γ production in response to repeat stimulation with BKV pepmixes	5 × 107T cells/m2	0	0	0	BKV cleared (1) BK partial response or reduced (2)

EBV, Epstein-Barr virus; PTLD, post-transplant lymphoproliferative disorder; CTL, cytotoxic T lymphocytes; CMV, cytomegalovirus; BKV, BK virus.